Visken Side Effects
Generic name: pindolol
Note: This document contains side effect information about pindolol. Some of the dosage forms listed on this page may not apply to the brand name Visken.
Some side effects of Visken may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to pindolol: oral tablet
Along with its needed effects, pindolol (the active ingredient contained in Visken) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pindolol:More common
- Swelling of the face, fingers, feet, or lower legs
- Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- chest pain
- difficult or labored breathing
- shortness of breath
- tightness in chest
- Decreased urine output
- dilated neck veins
- extreme fatigue
- fast, irregular, pounding, or racing heartbeat or pulse
- irregular breathing
- seeing, hearing, or feeling things that are not there
- troubled breathing
- weight gain
Get emergency help immediately if any of the following symptoms of overdose occur while taking pindolol:Symptoms of overdose
- Blurred vision
- pounding in the ears
- slow heartbeat
Some side effects of pindolol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Joint pain
- muscle pain
- trouble sleeping
- unable to sleep
- unusual tiredness or weakness
- Itching skin
- muscle cramps
- stomach soreness or discomfort
- unusual dreams
For Healthcare Professionals
Applies to pindolol: compounding powder, oral tablet
Like some other nonselective beta-blockers, pindolol (the active ingredient contained in Visken) may inhibit myocardial contractility. This may be important in some patients with left ventricular systolic dysfunction or congestive heart failure. Other cardiovascular side effects include bradycardia, edema with weight gain (reported in up to 15% of patients in some studies), Raynaud's phenomenon, cold extremities, and AV heart block. Palpitations are reported in less than 1% of patients.
Due to the intrinsic sympathomimetic activity of pindolol, induction or exacerbation of arrhythmias is possible, particularly when higher doses are used. At least one case of enhanced ventricular ectopic activity has been associated with pindolol.
Abrupt withdrawal of pindolol can result in significant hypertension, angina pectoris, and acute coronary insufficiency with myocardial infarction. This may be particularly important in some patients with a history of coronary artery disease.
A 47-year-old man with idiopathic dilated cardiomyopathy and premature ventricular depolarizations (PVDs) was stable on propranolol and digoxin (4 to 5 PVDs/min). Due to fear of negative inotropic activity, the patient was switched to pindolol during ECG monitoring. Fifteen minutes after the first dose of pindolol 10 mg orally, the PVD rate increased to 22 to 25/min, and six beats of nonsustained ventricular tachycardia (VT) were observed. Salvos of VT and ventricular couplets were observed. An idioventricular rhythm with a rate of 63 beats/min was also observed during episodes of sinus bradycardia. The serum digoxin level was 0.5 ng/mL; serum electrolytes were within normal limits. Pindolol therapy was not continued, and 10 hours later, the patient's ventricular ectopy returned to baseline.
Pindolol increases AV nodal conduction time, and may cause or exacerbate AV heart block due to digitalis or other reasons. The effect of pindolol on the AV node is less than propranolol.
Pindolol appears to cause orthostatic hypotension in a significant number of patients with autonomic dysfunction. In one study of seven patients with Shy Drager syndrome, two developed orthostatic changes and frank congestive heart failure at dosages of 15 mg three times a day.
Respiratory compromise has been observed in approximately 1% of patients. This may be very important in patients with reactive airways disease. While pindolol (the active ingredient contained in Visken) does have intrinsic sympathomimetic activity, its use in patients with bronchial asthma is limited.
A 35-year-old man with hypertension and type II diabetes mellitus developed lightheadedness and fell unconscious while skiing. Pertinent findings included hypothermia, hypotension, sinus bradycardia, "tented" T-waves on the ECG, and an undetectable blood glucose per fingerstick. The patient regained consciousness after intravenous glucose was given. He was accustomed to regular exercise, had not changed his pindolol (the active ingredient contained in Visken) dose (15 mg/day), but had not eaten a complete breakfast. The authors of this case report believe that, while the patient's glucose stores may have been low, the combined effects of exercise and beta-blockade on glucose metabolism caused the profound hypoglycemia.
Most data indicate (beneficial) significant decreases in total serum cholesterol and triglycerides and a significant increase of HDL cholesterol during pindolol therapy. Other data indicate significant increases in serum triglycerides and decreases of HDL cholesterol during pindolol therapy.
Endocrinologic abnormalities include hypoglycemia. Nonselective beta-blockers, such as pindolol, may inhibit catecholamine-mediated gluconeogenesis and mask the signs and symptoms of hypoglycemia, such as sweating and tachycardia. Data on the effect of pindolol on the lipid profile is controversial. Periodic monitoring of the lipid profile is suggested for patients with preexisting lipid disorders and in whom the consequences of hypercholesterolemia or hypertriglyceridemia are unacceptable.
Nervous system side effects include fatigue or unusual dreams in 5%, insomnia or dizziness in 3%, depression or headache in 2%, and nervousness or tremor in 1% of patients.
Rare cases of pindolol-induced tremor have been reported. While beta-blockers are known to suppress different types of tremors, the paradoxical appearance of tremors during pindolol therapy is attributed to its partial beta-agonist activity.
Gastrointestinal disturbances are unusual. Nausea or abdominal discomfort are reported in 2% of patients. Dry mouth or diarrhea are each reported in approximately 1% of patients.
In one placebo-controlled, double-blinded study of four beta-blockers in 30 healthy male volunteers, the nonselective beta-blockers, pindolol (the active ingredient contained in Visken) and propranolol, were associated with the greatest reduction in serum testosterone after one week of treatment. Pindolol was associated with the longest time to nocturnal penile tumescence. There were no statistically significant subjective complaints associated with these laboratory findings, however.
Genitourinary complaints are limited to decrease libido or impotence in approximately 1% of male patients.
Pindolol (the active ingredient contained in Visken) and carteolol, beta-adrenergic receptor antagonists with intrinsic sympathomimetic activity (ISA), have more commonly been associated with muscle cramps and elevated serum creatine phosphokinase (CK) levels than beta-blockers without ISA.
Musculoskeletal pain, usually presenting as muscle cramps, is reported in up to 3% of patients.
Renal side effects are not reported during pindolol (the active ingredient contained in Visken) therapy. Data show that the glomerular filtration rate and effective renal plasma flow are unaffected by pindolol.
More Visken resources
- Visken Prescribing Information (FDA)
- Visken Monograph (AHFS DI)
- Visken Concise Consumer Information (Cerner Multum)
- Visken Advanced Consumer (Micromedex) - Includes Dosage Information
- Pindolol Prescribing Information (FDA)
- Pindolol Professional Patient Advice (Wolters Kluwer)
- pindolol MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.